A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Recruiting now Phase 3 NCT07222137
Run by Eli Lilly and Company · for 1 to 35 · All sexes
What this study is about
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Who can join (things the study team will check)
✅ You may be able to join if…
- Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening
- Have Stage 1b or Stage 2 type 1 diabetes
- Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening
🚫 You may not be able to join if…
- Have any other type of diabetes
- Have uncontrolled high blood pressure
- Have had a heart attack, heart disease, stroke, or heart failure
- Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- Have a current or recent clinically serious infection
Where this trial is running
- Tallahassee Memorial HealthCare, Tallahassee, Florida, United States
- University of South Florida, Tampa, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States
- Novak Center for Children's Health, Louisville, Kentucky, United States
- Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
- University of Virginia, Charlottesville, Virginia, United States
- Women's and Children's Hospital, Adelaide, Australia
- Box Hill Hospital, Box Hill, Australia
- Royal Brisbane and Women's Hospital, Brisbane, Australia
- Centre for Children's Health Research, Brisbane, Australia
- Royal Children's Hospital, Melbourne, Australia
+ 98 more sites.
Who to contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07222137.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.